Arbutus Biopharma Files 8-K

TL;DR

Arbutus Biopharma filed an 8-K on June 5, 2024, reporting other events and financials.

AI Summary

Arbutus Biopharma Corporation filed an 8-K on June 5, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceuticals Corp, is incorporated in British Columbia, Canada, and its principal executive offices are located in Warminster, Pennsylvania.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and other events, which is important for investors to stay updated on the company's status.

Risk Assessment

Risk Level: low — This filing is a standard 8-K report for corporate events and financial statements, not indicating any immediate significant risks.

Key Players & Entities

• Arbutus Biopharma Corporation (company) — Registrant
• Tekmira Pharmaceuticals Corp (company) — Former company name
• June 5, 2024 (date) — Date of earliest event reported
• Warminster, Pennsylvania (location) — Principal Executive Offices

FAQ

Filing Documents

• f8k_060424.htm (8-K) — 15KB
• exh_991.htm (EX-99.1) — 14KB
• exh_992.htm (EX-99.2) — 33KB
• exh992_01.jpg (GRAPHIC) — 51KB
• exh992_02.jpg (GRAPHIC) — 159KB
• exh992_03.jpg (GRAPHIC) — 59KB
• exh992_04.jpg (GRAPHIC) — 86KB
• exh992_05.jpg (GRAPHIC) — 44KB
• exh992_06.jpg (GRAPHIC) — 70KB
• exh992_07.jpg (GRAPHIC) — 80KB
• exh992_08.jpg (GRAPHIC) — 58KB
• exh992_09.jpg (GRAPHIC) — 42KB
• exh992_10.jpg (GRAPHIC) — 63KB
• exh992_11.jpg (GRAPHIC) — 78KB
• exh992_12.jpg (GRAPHIC) — 97KB
• exh992_13.jpg (GRAPHIC) — 125KB
• exh992_14.jpg (GRAPHIC) — 109KB
• exh992_15.jpg (GRAPHIC) — 93KB
• exh992_16.jpg (GRAPHIC) — 127KB
• exh992_17.jpg (GRAPHIC) — 68KB
• exh992_18.jpg (GRAPHIC) — 63KB
• exh992_19.jpg (GRAPHIC) — 41KB
• exh992_20.jpg (GRAPHIC) — 83KB
• exh992_21.jpg (GRAPHIC) — 65KB
• exh992_22.jpg (GRAPHIC) — 95KB
• exh992_23.jpg (GRAPHIC) — 62KB
• exh992_24.jpg (GRAPHIC) — 58KB
• exh992_25.jpg (GRAPHIC) — 39KB
• 0001171843-24-003302.txt ( ) — 2912KB
• gnw-20190101.xsd (EX-101.SCH) — 3KB
• gnw-20190101_def.xml (EX-101.DEF) — 25KB
• gnw-20190101_lab.xml (EX-101.LAB) — 33KB
• gnw-20190101_pre.xml (EX-101.PRE) — 22KB
• f8k_060424_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On June 5, 2024, Arbutus Biopharma Corporation (the "Company") issued a press release announcing new data from its Phase 2a clinical trial IM-PROVE I (AB-729-201) showing that imdusiran, the Company's RNAi therapeutic, and 24 weeks of pegylated interferon alfa-2 (IFN), a standard-of-care immunomodulator, added to ongoing nucleos(t)ide analogue (NA) therapy, reduced HBsAg levels and led to sustained HBsAg loss in some patients with cHBV during and after treatment. These data were presented today in the Viral Hepatitis B and D: New therapies, unapproved therapies or strategies poster session, and will be featured during a poster tour on Thursday, June 6, 2024, at the European Association for the Study of the Liver (EASL) Congress. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. On June 5, 2024, the Company posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated June 5, 2024 99.1 Presentation dated June 5, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: June 5, 2024 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR